Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SPF harmonization

This article was originally published in The Rose Sheet

Executive Summary

The International Sun Protection Factor (SPF) Test Method, which sets a basis for harmonized strategy for substantiating claims on sun protection products worldwide, will initially be implemented in the EU, Japan and South Africa, the European Cosmetic, Toiletry and Perfumery Association announces. The industries, represented by their respective trade associations and joined by the U.S., signed the agreement June 1. More countries are expected to join the agreement, Colipa notes. In the U.S., FDA prescribes a method that differs "slightly," but the U.S. industry "supports and promotes the international method as the appropriate standard that all regulatory frameworks should move towards," Colipa adds. The industries of the four countries also will promote the test method as a standard of the International Standards Organization. In light of the agreement, "consumers can be assured that the same high-quality testing standard has been applied regardless of the country where they buy the products and authorities will have a tool to control the substantiation of SPF claims made by companies," Colipa adds...

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts